Narhex Life Sciences (ASX:NLS) has formed a new scientific advisory board, following Prof John Mills' appointment last week as managing director, replacing founder John Majewski, and the relocation of the company's head office to Melbourne.

"This advisory board has a broad range of both clinical and laboratory research experience, and is thus ideally constructed to give us sound, practical advice on the steps required for clinical development of our HIV protease inhibitor," said Mills in a statement.

The new appointees on the scientific advisory board include:

• David Cooper AO, a professor of medicine at the University of New South Wales (UNSW), director of the National Centre in HIV Epidemiology and Clinical Research and head of Immunology/HIV/Infectious Diseases Clinical Services Unit at St Vincent's Hospital, Sydney.
• Martyn French, clinical director of the Department of Clinical Immunology and Biochemical Genetics, Royal Perth Hospital and clinical professor of immunology, University of Western Australia, Perth.
• Damian Grobelny, who joined Narhex in 1990 to head its drug discovery program and is the inventor of the company's current HIV protease inhibitor candidate, DG35, and its prodrug, DG17.
• Jennifer Hoy, head of the Clinical Research Unit at the Alfred Hospital, Melbourne and associate professor of medicine at both Monash University and UNSW.
• Martin Hirsch, infectious disease physician and virologist at the Massachusetts General Hospital since 1971, professor of medicine at Harvard Medical School and professor of immunology and infectious diseases at the Harvard School of Public Health.
• Henry Krum, chair of medical therapeutics and professor of medicine at Monash University, and director of the NHMRC Centre of Clinical Research Excellence in Therapeutics.